Arvinas (ARVN) vs Fennec Pharmaceuticals (FENC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Fennec Pharmaceuticals (FENC) has outperformed Arvinas (ARVN) over the past year, gaining 21.1% versus a loss of 26.8%. Over five years, FENC leads with a +13.9% price change compared with -91.8% for ARVN. Arvinas is the larger company by market cap ($449.7 million vs $350.0 million), about 1.3 times the size.
Fennec Pharmaceuticals converts more of its revenue into profit, with a net margin of -21.8% versus -30.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARVN | FENC |
|---|---|---|
| Share price | $6.97 | $9.98 |
| Market cap | $449.71M | $349.97M |
| 1-day change | -2.65% | -3.57% |
| YTD return | -41.23% | +29.61% |
| 1-year return | -26.79% | +21.12% |
| 5-year return | -91.79% | +13.93% |
| P/E ratio (TTM) | 26.81 | — |
| Forward P/E | — | 10.53 |
| EPS (TTM) | $0.26 | $-0.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $262.60M | $44.64M |
| Revenue growth (YoY) | -0.30% | -6.09% |
| Net income (latest FY) | $-80.80M | $-9.74M |
| Operating margin | -45.13% | -14.07% |
| Net margin | -30.77% | -21.82% |
| 52-week high | $14.51 | $13.25 |
| 52-week low | $6.74 | $5.65 |
| Distance from 52-week high | -51.96% | -24.68% |
| Analyst consensus | buy | none |
| Avg. price target upside | +99.86% | +77.05% |
| Average volume | 800.32K | 188.89K |
| Shares outstanding | 64.52M | 35.07M |
| Employees | 246 | 35 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FENC has outperformed ARVN by 47.9 percentage points over the past year.
- Fennec Pharmaceuticals is more profitable, keeping -21.8 cents of every revenue dollar as net income versus -30.8 cents for Arvinas.
- Arvinas grew revenue faster in its latest fiscal year (-0.30% vs -6.09%).
About Arvinas
ARVN stock →Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Healthcare · Biotechnology · 246 employees
About Fennec Pharmaceuticals
FENC stock →Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.
Healthcare · Biotechnology · 35 employees
ARVN vs FENC FAQ
Which is bigger, Arvinas or Fennec Pharmaceuticals?
Arvinas (ARVN) is larger, with a market capitalization of $449.71M compared with $349.97M for Fennec Pharmaceuticals (FENC).
Which stock has performed better over the past year, ARVN or FENC?
FENC returned +21.12% over the past 12 months, compared with -26.79% for ARVN (price return, excluding dividends). Past performance does not predict future results.
Are Arvinas and Fennec Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.